文献速递肿瘤 PET/CT核素与放射性配体治疗

简化放射性标记方法在乳腺癌动物模型中对PARP抑制剂的评价

Evaluation of a simplified radiolabeling method for a PARP inhibitor in an animal model of breast cancer.
PubMed 文献 · EJNMMI Res · 2025-04-29

本研究在I-123/125-KX1的放射性碘标记流程中引入固相萃取(SPE)纯化步骤,并在乳腺癌细胞与动物模型中评价其结合特性与显像能力。结果显示产物放射化学纯度>99%,I-123-KX1放射化学产率为58.6%、I-125-KX1为73.3%;MDA-MB-231肿瘤摄取为6.9±0.8%ID/mL。作者认为SPE法制备的示踪剂具有与传统方法可比的性质,但可能还需进一步表征研究确认其效力。

要点

  • SPE纯化后I-123/125-KX1放射化学纯度>99%,I-123-KX1产率58.6%、I-125-KX1产率73.3%。
  • 示踪剂Kd约1.0 nM,MDA-MB-231与MCF-7细胞Bmax分别为2017±178与1393±105 fmol/mg。
  • MDA-MB-231荷瘤模型肿瘤摄取6.9±0.8%ID/mL,放射自显影与PARP-1免疫组化模式相似。

核心结论

  • 作者认为SPE法制备的I-123/125-KX1显示出与传统方法一些可比的性质,提示其可能适合未来PARP研究中的放射性配体制备。
  • 作者指出可能还需要进一步表征研究来确认其效力。

研究设计与样本

  • 研究在放射性碘标记流程中采用固相萃取(SPE)作为最终纯化步骤制备I-123/125-KX1。
  • 通过受体结合试验、放射自显影和体内单光子发射计算机断层扫描(SPECT)显像技术评价其结合特异性。
  • 体外结合特性在MDA-MB-231与MCF-7细胞上通过饱和结合试验验证。
  • 体内显像能力在MDA-MB-231肿瘤动物模型上展示。

主要发现

  • SPE纯化后I-123/125-KX1放射化学纯度>99%,放射化学产率I-123-KX1为58.6%、I-125-KX1为73.3%。
  • 示踪剂Kd值约1.0 nM,与文献报道值一致;Bmax在MDA-MB-231为2017±178 fmol/mg、在MCF-7为1393±105 fmol/mg,与Western blot分析结果相符。
  • I-123-KX1在MDA-MB-231肿瘤组织中显示合适摄取,为6.9±0.8%ID/mL。
  • SPE纯化的I-125-KX1结合特异性通过体外放射自显影联合多种PARP抑制剂进一步验证。
  • 抗PARP-1免疫组化实验显示放射自显影模式与免疫组化结果相似。

局限性

  • 作者指出可能还需要进一步表征研究来确认其效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors were recently approved by the US Food and Drug Administration for use in cancer treatment. To facilitate the discovery of novel PARP-targeting ligands, a radioiodinated ligand, I-125-KX1, was developed and validated for its specificity to PARP-1; however, its preparation procedure is time-consuming. The present study employed a solid-phase extraction (SPE) method in the radiolabeling procedure of I-123/125-KX1 and evaluated its binding specificity by using receptor binding assays, autoradiography, and in vivo single photon emission computed tomography (SPECT) imaging technique. RESULTS: Through the incorporation of the SPE purification method as the final step in the radioiodination procedure, the resultant product I-123/125-KX1 exhibited high radiochemical purity (> 99%) and an acceptable radiochemical yield (58.6% for I-123-KX1, 73.3% for I-125-KX1). The binding characteristics of this radiotracer were validated through saturation binding assays conducted on MDA-MB-231 and MCF-7 cells. The Kd values obtained for the tracer (~ 1.0 nM) was consistent with values reported in the literature, and the Bmax values of these two cell lines (2017 ± 178 fmol/mg on MDA-MB-231 vs. 1393 ± 105 fmol/mg on MCF-7) were in line with the results from Western blot analyses. To demonstrate the in vivo imaging ability of I-123-KX1 prepared in this study, an MDA-MB-231 tumor animal model was used and the tracer displayed a suitable uptake on the tumor tissues (6.9 ± 0.8%ID/mL). The binding specificity of the SPE-purified I-125-KX1 was further verified using in vitro autoradiography in conjunction with various PARP inhibitors. Additionally, an anti-PARP-1 immunohistochemistry experiment was conducted, which revealed that the autoradiograms of the radiotracer displayed a similar pattern. CONCLUSIONS: This suggests that the I-123/125-KX1 prepared using the SPE method showed some comparable properties to those from the traditional method, indicating its potential suitability for future radioligand preparation in PARP studies. However, further characterization studies may be needed to confirm its efficacy.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Weng CC, Chiang CC, Chung YH, et al. Evaluation of a simplified radiolabeling method for a PARP inhibitor in an animal model of breast cancer. EJNMMI Res. 2025. PMID: 40301197. doi:10.1186/s13550-025-01236-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。